{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:03:51Z","timestamp":1753887831333},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>Exclusive enteral nutrition is recommended as a first-line treatment in active pediatric Crohn\u2019s Disease, but its mechanism of action is still not clear. We aimed to assess alterations in the metabolic profile of newly diagnosed pediatric Crohn\u2019s Disease patients before and during exclusive enteral nutrition therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Plasma samples from 14 pediatric Crohn\u2019s Disease patients before and after 3\u20134 weeks on exclusive enteral nutrition were analyzed using mass spectrometry. T-test, fold change and orthogonal partial least squares discriminant analysis were used for mining significant features. Correlation analysis was performed between the annotated features and the weighted pediatric Crohn\u2019s disease activity index using Pearson r distance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 13 compounds which decreased during exclusive enteral nutrition, most are related to diet, while one is a bacterial metabolite, Bacteriohopane-32,33,34,35-tetrol. The phosphatidic acid metabolite PA(15:1\/18:0) was significantly reduced and correlated with the weighted pediatric Crohn\u2019s disease activity index. Lipids increased during exclusive enteral nutrition therapy included phosphatidylethanolamines; PE(24:1\/24:1), PE(17:2\/20:2) and one lactosylceramide; LacCer(d18:1\/14:0).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Food additives and other phytochemicals were the major metabolites, which decreased following the exclusion of a regular diet during exclusive enteral nutrition. An alteration in bacterial biomarkers may reflect changes in intestinal microbiota composition and metabolism. Thus, metabolomics provides an opportunity to characterize the molecular mechanisms of dietary factors triggering Crohn\u2019s Disease activity, and the mechanisms of action of exclusive enteral nutrition, thereby providing the basis for the development and evaluation of improved intervention strategies for prevention and treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11306-022-01953-0","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T17:57:34Z","timestamp":1669399054000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Metabolic changes during exclusive enteral nutrition in pediatric Crohn\u2019s disease patients"],"prefix":"10.1007","volume":"18","author":[{"given":"Jair G.","family":"Marques","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Schwerd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Bufler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Koletzko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthold","family":"Koletzko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"1953_CR1","unstructured":"Sasson, A. N., Ananthakrishnan, A. N., & Raman, M. (2019). Diet in treatment of inflammatory bowel diseases.Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"1953_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jgh.12751","volume":"30","author":"C Fiocchi","year":"2015","unstructured":"Fiocchi, C. (2015). Inflammatory bowel disease pathogenesis: Where are we? Journal Of Gastroenterology And Hepatology, 30(Suppl 1), 12\u201318.","journal-title":"Journal Of Gastroenterology And Hepatology"},{"key":"1953_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clnu.2018.01.020","volume":"38","author":"JJ Ashton","year":"2019","unstructured":"Ashton, J. J., Gavin, J., & Beattie, R. M. (2019). Exclusive enteral nutrition in crohn\u2019s disease: Evidence and practicalities. Clinical Nutrition, 38, 80\u201389.","journal-title":"Clinical Nutrition"},{"key":"1953_CR4","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.3748\/wjg.v19.i43.7652","volume":"19","author":"CL Wall","year":"2013","unstructured":"Wall, C. L., Day, A. S., & Gearry, R. B. (2013). Use of exclusive enteral nutrition in adults with crohn\u2019s disease: A review. World Journal Of Gastroenterology, 19, 7652\u20137660.","journal-title":"World Journal Of Gastroenterology"},{"key":"1953_CR5","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/apt.12770","volume":"39","author":"K Frivolt","year":"2014","unstructured":"Frivolt, K., Schwerd, T., Werkstetter, K. J., et al. (2014). Repeated exclusive enteral nutrition in the treatment of paediatric crohn\u2019s disease: Predictors of efficacy and outcome. Alimentary Pharmacology & Therapeutics, 39, 1398\u20131407.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"1953_CR6","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","volume":"8","author":"FM Ruemmele","year":"2014","unstructured":"Ruemmele, F. M., Veres, G., Kolho, K. L., et al. (2014). Consensus guidelines of ecco\/espghan on the medical management of pediatric crohn\u2019s disease. J Crohns Colitis, 8, 1179\u20131207.","journal-title":"J Crohns Colitis"},{"key":"1953_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12519-018-0204-0","volume":"15","author":"Y Yu","year":"2019","unstructured":"Yu, Y., Chen, K. C., & Chen, J. (2019). Exclusive enteral nutrition versus corticosteroids for treatment of pediatric crohn\u2019s disease: A meta-analysis. World Journal of Pediatrics, 15, 26\u201336.","journal-title":"World Journal of Pediatrics"},{"key":"1953_CR8","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/j.1440-1746.2006.04294.x","volume":"21","author":"AS Day","year":"2006","unstructured":"Day, A. S., Whitten, K. E., Lemberg, D. A., et al. (2006). Exclusive enteral feeding as primary therapy for crohn\u2019s disease in australian children and adolescents: A feasible and effective approach. Journal Of Gastroenterology And Hepatology, 21, 1609\u20131614.","journal-title":"Journal Of Gastroenterology And Hepatology"},{"key":"1953_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000350369","volume":"63","author":"KJ Werkstetter","year":"2013","unstructured":"Werkstetter, K. J., Schatz, S. B., Alberer, M., Filipiak-Pittroff, B., & Koletzko, S. (2013). Influence of exclusive enteral nutrition therapy on bone density and geometry in newly diagnosed pediatric crohn\u2019s disease patients. Annals Of Nutrition & Metabolism, 63, 10\u201316.","journal-title":"Annals Of Nutrition & Metabolism"},{"key":"1953_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2036.2008.03796.x","volume":"28","author":"ST Leach","year":"2008","unstructured":"Leach, S. T., Mitchell, H. M., Eng, W. R., Zhang, L., & Day, A. S. (2008). Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with crohn\u2019s disease. Alimentary Pharmacology & Therapeutics, 28, 724\u2013733.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"1953_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.dld.2012.04.014","volume":"44","author":"H Shiga","year":"2012","unstructured":"Shiga, H., Kajiura, T., Shinozaki, J., et al. (2012). Changes of faecal microbiota in patients with crohn\u2019s disease treated with an elemental diet and total parenteral nutrition. Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver, 44, 736\u2013742.","journal-title":"Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver"},{"key":"1953_CR12","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1177\/01486071050290S4S173","volume":"29","author":"P Lionetti","year":"2005","unstructured":"Lionetti, P., Callegari, M. L., Ferrari, S., et al. (2005). Enteral nutrition and microflora in pediatric crohn\u2019s disease. Jpen. Journal Of Parenteral And Enteral Nutrition, 29, S173\u2013S175. discussion S5-8.","journal-title":"Jpen. Journal Of Parenteral And Enteral Nutrition"},{"key":"1953_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/MIB.0000000000000023","volume":"20","author":"K Gerasimidis","year":"2014","unstructured":"Gerasimidis, K., Bertz, M., Hanske, L., et al. (2014). Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric crohn\u2019s disease during enteral nutrition. Inflammatory Bowel Diseases, 20, 861\u2013871.","journal-title":"Inflammatory Bowel Diseases"},{"key":"1953_CR14","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1038\/ctg.2014.21","volume":"6","author":"NO Kaakoush","year":"2015","unstructured":"Kaakoush, N. O., Day, A. S., Leach, S. T., et al. (2015). Effect of exclusive enteral nutrition on the microbiota of children with newly diagnosed crohn\u2019s disease. Clin Transl Gastroenterol, 6, e71.","journal-title":"Clin Transl Gastroenterol"},{"key":"1953_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaci.2015.12.1331","volume":"138","author":"T Schwerd","year":"2016","unstructured":"Schwerd, T., Frivolt, K., Clavel, T., et al. (2016). Exclusive enteral nutrition in active pediatric crohn disease: Effects on intestinal microbiota and immune regulation. The Journal Of Allergy And Clinical Immunology, 138, 592\u2013596.","journal-title":"The Journal Of Allergy And Clinical Immunology"},{"key":"1953_CR16","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/ajg.2015.357","volume":"110","author":"C Quince","year":"2015","unstructured":"Quince, C., Ijaz, U. Z., Loman, N., et al. (2015). Extensive modulation of the fecal metagenome in children with crohn\u2019s disease during exclusive enteral nutrition. American Journal Of Gastroenterology, 110, 1718\u20131729. quiz 30.","journal-title":"American Journal Of Gastroenterology"},{"key":"1953_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gutjnl-2015-311058","volume":"66","author":"C Guinet-Charpentier","year":"2017","unstructured":"Guinet-Charpentier, C., Lepage, P., Morali, A., Chamaillard, M., & Peyrin-Biroulet, L. (2017). Effects of enteral polymeric diet on gut microbiota in children with crohn\u2019s disease. Gut, 66, 194\u2013195.","journal-title":"Gut"},{"key":"1953_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/nu9050447","volume":"9","author":"AC MacLellan","year":"2017","unstructured":"MacLellan, A. C., Grant, J., Cahill, S., Langille, L., & Van Limbergen, M. G. I. (2017). The impact of exclusive enteral nutrition (een) on the gut microbiome in crohn\u2019s disease: A review. Nutrients, 9, 447.","journal-title":"Nutrients"},{"key":"1953_CR19","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/gb-2012-13-9-r79","volume":"13","author":"XC Morgan","year":"2012","unstructured":"Morgan, X. C., Tickle, T. L., Sokol, H., et al. (2012). Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biology, 13, R79.","journal-title":"Genome Biology"},{"key":"1953_CR20","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/ejcn.2016.74","volume":"70","author":"C Walton","year":"2016","unstructured":"Walton, C., Montoya, M. P., Fowler, D. P., et al. (2016). Enteral feeding reduces metabolic activity of the intestinal microbiome in crohn\u2019s disease: An observational study. European Journal Of Clinical Nutrition, 70, 1052\u20131056.","journal-title":"European Journal Of Clinical Nutrition"},{"key":"1953_CR21","doi-asserted-by":"publisher","first-page":"18879","DOI":"10.1038\/s41598-020-75306-z","volume":"10","author":"K Diederen","year":"2020","unstructured":"Diederen, K., Li, J. V., Donachie, G. E., et al. (2020). Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with crohn\u2019s disease. Scientific reports, 10, 18879.","journal-title":"Scientific reports"},{"key":"1953_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrm.2016.25","volume":"17","author":"CH Johnson","year":"2016","unstructured":"Johnson, C. H., Ivanisevic, J., Siuzdak, G., & Metabolomics (2016). Beyond biomarkers and towards mechanisms. Nature Reviews Molecular Cell Biology, 17, 451\u2013459.","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"1953_CR23","first-page":"321","volume":"11","author":"KL Kolho","year":"2016","unstructured":"Kolho, K. L., Pessia, A., Jaakkola, T., de Vos, W. M., & Velagapudi, V. (2016). Faecal and serum metabolomics in paediatric inflammatory bowel disease. Journal of Crohn\u2019s and Colitis, 11, 321\u2013334.","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"1953_CR24","doi-asserted-by":"publisher","first-page":"814839","DOI":"10.3389\/fmed.2022.814839","volume":"9","author":"H Liu","year":"2022","unstructured":"Liu, H., Xu, M., He, Q., et al. (2022). Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with crohn\u2019s disease. Front Med (Lausanne), 9, 814839.","journal-title":"Front Med (Lausanne)"},{"key":"1953_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ibd\/izy402","volume":"25","author":"U Daniluk","year":"2019","unstructured":"Daniluk, U., Daniluk, J., Kucharski, R., et al. (2019). Untargeted metabolomics and inflammatory markers profiling in children with crohn\u2019s disease and ulcerative colitis-a preliminary study. Inflammatory Bowel Diseases, 25, 1120\u20131128.","journal-title":"Inflammatory Bowel Diseases"},{"key":"1953_CR26","unstructured":"Marques, J. G., Shokry, E., Frivolt, K., et al. Metabolomic signatures in pediatric crohn\u2019s disease patients with mild or quiescent disease treated with partial enteral nutrition: A feasibility study.SLAS TECHNOLOGY: Translating Life Sciences Innovation;0:2472630320969147."},{"key":"1953_CR27","first-page":"1","volume":"68","author":"DSW Jasmine Chong","year":"2019","unstructured":"Jasmine Chong, D. S. W., & Jianguo Xia. (2019). Using metaboanalyst 4.0 for comprehensive and integrative metabolomics data analysis. Current protocols in bioinformatics, 68, 1\u2013128.","journal-title":"Current protocols in bioinformatics"},{"key":"1953_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ibd.21649","volume":"18","author":"D Turner","year":"2011","unstructured":"Turner, D., Griffiths, A. M., Walters, T. D., et al. (2011). Mathematical weighting of the pediatric crohn\u2019s disease activity index (pcdai) and comparison with its other short versions. Inflammatory Bowel Diseases, 18, 55\u201362.","journal-title":"Inflammatory Bowel Diseases"},{"key":"1953_CR29","first-page":"149","volume":"158","author":"CA Shively","year":"1984","unstructured":"Shively, C. A., & Tarka, S. M. (1984). Jr. Methylxanthine composition and consumption patterns of cocoa and chocolate products. Progress In Clinical And Biological Research, 158, 149\u2013178.","journal-title":"Progress In Clinical And Biological Research"},{"key":"1953_CR30","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S., Tzur, D., Knox, C., et al. (2007). Hmdb: The human metabolome database. Showing metabocard for (+\/-)-3-[(2-methyl-3-furyl)thio]-2-butanone (hmdb0032401. Nucleic Acids Research, 35, D521\u2013D526.","journal-title":"Nucleic Acids Research"},{"key":"1953_CR31","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S., Tzur, D., Knox, C., et al. (2007). Hmdb: The human metabolome database. Showing metabocard for 3-(3,4-dihydroxyphenyl)-1-propanol 3\u2019-glucoside (hmdb0038304). Nucleic Acids Research, 35, D521\u2013D526.","journal-title":"Nucleic Acids Research"},{"key":"1953_CR32","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S., Tzur, D., Knox, C., et al. (2007). Hmdb: The human metabolome database. Nucleic Acids Research, 35, D521\u2013D526.","journal-title":"Nucleic Acids Research"},{"key":"1953_CR33","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S., Tzur, D., Knox, C., et al. (2007). Hmdb: The human metabolome database. Showing metabocard for n-nitrosotomatidine (hmdb0034102). Nucleic Acids Research, 35, D521\u2013D526.","journal-title":"Nucleic Acids Research"},{"key":"1953_CR34","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S., Tzur, D., Knox, C., et al. (2007). Hmdb: The human metabolome database. Showing metabocard for amino (methoxysulfinyl) pentasulfide (hmdb0031980). Nucleic Acids Research, 35, D521\u2013D526.","journal-title":"Nucleic Acids Research"},{"key":"1953_CR35","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S., Tzur, D., Knox, C., et al. (2007). Hmdb: The human metabolome database. Showing metabocard for 4-(3-hydroxy-7-phenyl-6-heptenyl)-1,2-benzenediol (hmdb0041089). Nucleic Acids Research, 35, D521\u2013D526.","journal-title":"Nucleic Acids Research"},{"key":"1953_CR36","doi-asserted-by":"crossref","unstructured":"Van Engen, D., Clardy, J., Kho-Wiseman, E., et al. (1978). Violacene: A reassignment of structure. Tetrahedron Letters ;19:29\u201332.","DOI":"10.1016\/S0040-4039(01)88974-7"},{"key":"1953_CR37","doi-asserted-by":"publisher","first-page":"465056","DOI":"10.1155\/2015\/465056","volume":"2015","author":"SY Choi","year":"2015","unstructured":"Choi, S. Y., Yoon, K. H., Lee, J. I., & Mitchell, R. J. (2015). Violacein: Properties and production of a versatile bacterial pigment. Biomed Research International, 2015, 465056.","journal-title":"Biomed Research International"},{"key":"1953_CR38","doi-asserted-by":"publisher","first-page":"17558","DOI":"10.1073\/pnas.1314017110","volume":"110","author":"M Alhouayek","year":"2013","unstructured":"Alhouayek, M., Masquelier, J., Cani, P. D., Lambert, D. M., & Muccioli, G. G. (2013). Implication of the anti-inflammatory bioactive lipid prostaglandin d2-glycerol ester in the control of macrophage activation and inflammation by abhd6. Proceedings of the National Academy of Sciences of the United States of America, 110, 17558\u201317563.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"1953_CR39","doi-asserted-by":"publisher","first-page":"4829180","DOI":"10.1155\/2017\/4829180","volume":"2017","author":"D Patel","year":"2017","unstructured":"Patel, D., & Witt, S. N. (2017). Ethanolamine and phosphatidylethanolamine: Partners in health and disease. Oxidative Medicine and Cellular Longevity, 2017, 4829180.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"1953_CR40","doi-asserted-by":"publisher","first-page":"eaaz6333","DOI":"10.1126\/sciadv.aaz6333","volume":"6","author":"M Bogdanov","year":"2020","unstructured":"Bogdanov, M., Pyrshev, K., Yesylevskyy, S., et al. (2020). Phospholipid distribution in the cytoplasmic membrane of gram-negative bacteria is highly asymmetric, dynamic, and cell shape-dependent. Science Advances, 6, eaaz6333.","journal-title":"Science Advances"},{"key":"1953_CR41","doi-asserted-by":"publisher","first-page":"D521","DOI":"10.1093\/nar\/gkl923","volume":"35","author":"DS Wishart","year":"2007","unstructured":"Wishart, D. S., Tzur, D., Knox, C., et al. (2007). Hmdb: The human metabolome database. Showing metabocard for 3,5-diiodo-l-tyrosine (hmdb0003474). Nucleic Acids Research, 35, D521\u2013D526.","journal-title":"Nucleic Acids Research"},{"key":"1953_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1136\/gut.29.5.580","volume":"29","author":"CR Stevens","year":"1988","unstructured":"Stevens, C. R., Oberholzer, V. G., Walker-Smith, J. A., & Phillips, A. D. (1988). Lactosylceramide in inflammatory bowel disease: A biochemical study. Gut, 29, 580\u2013587.","journal-title":"Gut"},{"key":"1953_CR43","doi-asserted-by":"crossref","unstructured":"Filimoniuk, A., Blachnio-Zabielska, A., Imierska, M., Lebensztejn, D. M., & Daniluk, U. (2020). Sphingolipid analysis indicate lactosylceramide as a potential biomarker of inflammatory bowel disease in children.Biomolecules;10.","DOI":"10.3390\/biom10071083"},{"key":"1953_CR44","doi-asserted-by":"publisher","first-page":"J51","DOI":"10.3314\/mmj.18.008","volume":"59","author":"K Iwabuchi","year":"2018","unstructured":"Iwabuchi, K. (2018). [lactosylceramide-enriched lipid raft-mediated infection immunity]. Med Mycol J, 59, J51\u2013j61.","journal-title":"Med Mycol J"},{"key":"1953_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3109\/10799893.2011.625428","volume":"31","author":"J L\u00e1ng","year":"2011","unstructured":"L\u00e1ng, J., R\u00e1k\u00e1sz, V., Magyar, A., P\u00e1llinger, \u00c9., & K\u0151hidai, L. (2011). Chemotactic effect of odorants and tastants on the ciliate tetrahymena pyriformis. Journal of Receptors and Signal Transduction, 31, 423\u2013433.","journal-title":"Journal of Receptors and Signal Transduction"},{"key":"1953_CR46","doi-asserted-by":"publisher","first-page":"1934578X0700200","DOI":"10.1177\/1934578X0700200315","volume":"2","author":"MSC Pedras","year":"2007","unstructured":"Pedras, M. S. C., Zheng, Q., & Sarma-Mamillapalle, V. K. (2007). The phytoalexins from brassicaceae: Structure, biological activity, synthesis and biosynthesis. Natural Product Communications, 2, 1934578X0700200315.","journal-title":"Natural Product Communications"},{"key":"1953_CR47","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1080\/14756366.2020.1722120","volume":"35","author":"AAM Abdel-Aziz","year":"2020","unstructured":"Abdel-Aziz, A. A. M., El-Azab, A. S., AlSaif, N. A., et al. (2020). Synthesis, anti-inflammatory, cytotoxic, and cox-1\/2 inhibitory activities of cyclic imides bearing 3-benzenesulfonamide, oxime, and \u03b2-phenylalanine scaffolds: A molecular docking study. Journal of Enzyme Inhibition and Medicinal Chemistry, 35, 610\u2013621.","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"key":"1953_CR48","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1574-6968.2000.tb08974.x","volume":"183","author":"JH Cvejic","year":"2000","unstructured":"Cvejic, J. H., Putra, S. R., El-Beltagy, A., et al. (2000). Bacterial triterpenoids of the hopane series as biomarkers for the chemotaxonomy of burkholderia, pseudomonas and ralstonia spp. Fems Microbiology Letters, 183, 295\u2013299.","journal-title":"Fems Microbiology Letters"},{"key":"1953_CR49","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.3389\/fmicb.2018.03220","volume":"9","author":"V Dinakaran","year":"2019","unstructured":"Dinakaran, V., Mandape, S. N., Shuba, K., et al. (2019). Identification of specific oral and gut pathogens in full thickness colon of colitis patients: Implications for colon motility. Frontiers In Microbiology, 9, 3220.","journal-title":"Frontiers In Microbiology"},{"key":"1953_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40168-018-0604-3","volume":"7","author":"H Armstrong","year":"2019","unstructured":"Armstrong, H., Alipour, M., Valcheva, R., et al. (2019). Host immunoglobulin g selectively identifies pathobionts in pediatric inflammatory bowel diseases. Microbiome, 7, 1.","journal-title":"Microbiome"},{"key":"1953_CR51","doi-asserted-by":"publisher","first-page":"13780","DOI":"10.1073\/pnas.0706625104","volume":"104","author":"DN Frank","year":"2007","unstructured":"Frank, D. N., St Amand, A. L., Feldman, R. A., et al. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences of the United States of America, 104, 13780\u201313785.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"1953_CR52","doi-asserted-by":"publisher","first-page":"13473","DOI":"10.1038\/s41598-019-49833-3","volume":"9","author":"MK Vester-Andersen","year":"2019","unstructured":"Vester-Andersen, M. K., Mirsepasi-Lauridsen, H. C., Prosberg, M. V., et al. (2019). Increased abundance of proteobacteria in aggressive crohn\u2019s disease seven years after diagnosis. Scientific reports, 9, 13473.","journal-title":"Scientific reports"},{"key":"1953_CR53","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/np980406d","volume":"62","author":"FQ Alali","year":"1999","unstructured":"Alali, F. Q., Liu, X. X., & McLaughlin, J. L. (1999). Annonaceous acetogenins: Recent progress. Journal of Natural Products, 62, 504\u2013540.","journal-title":"Journal of Natural Products"},{"key":"1953_CR54","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.bbalip.2009.04.001","volume":"1791","author":"EE Kooijman","year":"2009","unstructured":"Kooijman, E. E., & Burger, K. N. J. (2009). Biophysics and function of phosphatidic acid: A molecular perspective. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1791, 881\u2013888.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"},{"key":"1953_CR55","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Pel\u00e1ez, S., Camps-Bossacoma, M., Massot-Cladera, M., et al. (2017). Effect of cocoa\u2019s theobromine on intestinal microbiota of rats.Molecular nutrition & food research;61.","DOI":"10.1002\/mnfr.201700238"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-022-01953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11306-022-01953-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-022-01953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T07:07:23Z","timestamp":1671692843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11306-022-01953-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":55,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1953"],"URL":"https:\/\/doi.org\/10.1007\/s11306-022-01953-0","relation":{},"ISSN":["1573-3890"],"issn-type":[{"value":"1573-3890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"30 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JGM has nothing to declare. SK reports personal fees from Nestle, Danone, Biocodex, Shire, Abbvie, Pharmacosmos, Janssen, Pfizer, Takeda, Mead-Johnson, and research grants paid to the institution from Mead Johnson outside the submitted work. BK benefitted from support for scientific or educational activities from Barilla, Bayer, Cheplapharm, Cogitando, Danone, DSM, DGC, Hipp, Nestl\u00e9, and Reckitt Benkiser. TS received speaker\u2019s fees from MSD and Nutricia. PB received personal fees (lectures, advisory board) from AbbVie, Orphalan, Mirum, Amgen, Nestl\u00e9 Nutrition Institute, Nutricia, and Albireo with no activities connected to the presented work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"96"}}